The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1542511
This article is part of the Research Topic Enhancing Prostate Cancer Diagnosis: Biomarkers and Imaging for Improved Patient Outcomes View all 3 articles
New biomarkers and multiplex tests for diagnosis of aggressive prostate cancer and therapy management
Provisionally accepted- 1 Department of Urology, University Hospital Olomouc, Olomouc, Czechia
- 2 Department of Clinical and Molecular Pathology, University Hospital Olomouc, Olomouc, Olomouc, Czechia
Dear reviewers, on behalf of the entire team of authors, I would like to thank you for your comments. We perceive them as stimuli to improve the clarity and contribution of our article to the readers. We incorporated your comments, supplemented the literature with other works and developed an overview table focused on the most used biomarkers. We strongly believe that you will be satisfied and if you still find place for additions or improvements, we thank you in advance for further suggestions.Changes in text are in blue.Reviewer No. 1 -section numbers were assigned based on the type of markers -methods were summarized in a Table 2.Reviewer No. 2 -requested larger discussion on parameters, risk and limitations was implemented in section 5 and in Table 2 with specific recommendation which test for which patient/ risk group -Section 5 was completedly revised, made more robust and specific with emphasis on clinical consequences of the tests
Keywords: Prostate, Cancer, biomarker, test, Treatment, prognosis
Received: 09 Dec 2024; Accepted: 06 Feb 2025.
Copyright: © 2025 Kral, Kurfurstova, Zemla, Elias and Bouchal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Daniela Kurfurstova, Department of Clinical and Molecular Pathology, University Hospital Olomouc, Olomouc, 779 00, Olomouc, Czechia
Pavel Zemla, Department of Urology, University Hospital Olomouc, Olomouc, Czechia
Martin Elias, Department of Clinical and Molecular Pathology, University Hospital Olomouc, Olomouc, 779 00, Olomouc, Czechia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.